Slider
Schumann et al. 2020 – Pharmacology Review
Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease

 

Parhofer et al. 2019 – ExpClin Endocrinol Diabetes
Position Paper on Lipid Therapy in Patients with Diabetes Mellitus.

 

Angelini et al. 2019 – Sci Rep
New insight into the mechanisms of ectopic fat deposition improvement after bariatric surgery.

 

Husain et al. 2019 – NEJM
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

 

El-Agroudy et al. 2019 – Cell Metabolism
Are Lifestyle Therapies Effective for NAFLD Treatment?

 

Reuter and Jordan 2019 – Curr Opin Cardiol
Status of hypertension in Europe.

 

Selch et al. – 2018 Sci Rep
Analysis of naturally occurring mutations in the human uptake transporter NaCT important for bone and brain development and energy metabolism.

 

Jordan et al. 2018 – Hypertension
Natriuretic Peptides in Cardiovascular and Metabolic Crosstalk: Implications for Hypertension Management.

 

Willmes et al. 2018 – Pharmacol Ther.
Review: The longevity gene INDY (I’m Not Dead Yet) in metabolic control: Potential as pharmacological target

 

von Loeffelholz et al. 2017 – Hepatology
The Human Longevity Gene Homolog INDY and Interleukin-6 Interact in Hepatic Lipid Metabolism

 

Brachs et al. 2016 – Molecular Metabolism
Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice

 

Willmes et al. 2016 – Aging
The longevity transporter mIndy (Slc13a5) as a target for treating hepatic steatosis and insulin resistance

 

Jordan and Birkenfeld 2016 – Rev Endocr Metab Disord
Cardiometabolic crosstalk in obesity-associated arterial hypertension

 

Jordan et al. 2015 – J Hypertension
Joint scientific statement of the European Association for the Study of Obesity and the European Society of Hypertension: Obesity and early vascular ageing.

 

Neuschaefer-Rube et al. 2015 – Toxicology
Arylhydrocarbon receptor (AhR) dependent mIndy (Slc13a5) induction as possible contributor to benzo[a]pyrene induced lipid accumulation in hepatocytes

 

Schwarz et al. 2015 – Aging
Knockdown of Indy/CeNac2 extends Caenorhabditis elegans life span by inducing AMPK/aak‐2.

 

Pesta et al. 2015 – Aging
Prevention of diet‐induced hepatic steatosis and hepatic insulin resistance by second generation antisense oligonucleotides targeted to the longevity gene mIndy (Slc13a5).

 

Neuschaefer-Rube et al. 2013 – Diabetes
The Mammalian INDY Homolog is Induced by cAMP responsive-element-binding protein (CREB) in a Rat Model of Type 2 Diabetes.

 

Willmes and Birkenfeld 2013 – Comp Struct Biotech J
The Role of INDY in Metabolic Regulation (Review)

 

Birkenfeld et al. 2011 – Cell Metab
Deletion of the Mammalian INDY Homolog Mimics Aspects of Dietary Restriction and Protects against Adiposity and Insulin Resistance in Mice.
Hu et al. 2020 – Toxicol App Pharmacol
Comparative proteomic analysis of SLC13A5 knockdown reveals elevated ketogenesis and enhanced cellular toxic response to chemotherapeutic agents in HepG2 cells.

 

Kopel et al. 2020 – Sci Rep
The Hepatic Plasma Membrane Citrate Transporter NaCT (SLC13A5) as a Molecular Target for Metformin.

 

Poolsri et al. 2018 – Biomed Res Int
Combination of Mitochondrial and Plasma Membrane Citrate Transporter Inhibitors Inhibits De Novo Lipogenesis Pathway and Triggers Apoptosis in Hepatocellular Carcinoma Cells.

 

Phokrai et al. 2018 – FEBS Open Bio
Suppressed de novo lipogenesis by plasma membrane citrate transporter inhibitor promotes apoptosis in HepG2 cells.

 

Peters 2017 – J Biol. Chem
Flipping a citrate switch on liver cancer cells.

 

Li et al. 2017 – J Biol Chem
Silencing of solute carrier family 13 member 5 disrupts energy homeostasis and inhibits proliferation of human hepatocarcinoma cells

 

Rogina 2017 – Frontiers in Genetics
INDY-A New Link to Metabolic Regulation in Animals and Humans

 

Pajor et al. 2016 – Molecular Pharmacology
Molecular Basis for Inhibition of the Na+/Citrate Transporter NaCT (SLC13A5) by Dicarboxylate Inhibitors

 

Rives et al. 2016 – Molecular Pharmacology
State-Dependent Allosteric Inhibition of the Human SLC13A5 Citrate Transporter by Hydroxysuccinic Acids, PF-06649298 and PF-06761281

 

Huard et al. 2016 – J Med Chem
Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) Family

 

Huard et al. 2015 – Sci Rep
Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5)

 

Hardies et al. 2015 – Brain
Recessive mutations in SLC13A5 result in a loss of citrate transport and cause neonatal epilepsy, developmental delay and teeth hypoplasia

 

Gopal et al. 2015 – J Pharmacol Exp Ther
Species-specific Influence of Lithium on the Activity of SLC13A5 (NaCT): Lithium-induced Activation is Specific for the Transporter in Primates.

 

Mancusso et al. 2012 – Nature
Structure and mechanism of a bacterial sodium-dependent dicarboxylate transporter (crystal structure of vcINDY, a bacterial homologue of INDY, NaCT).

 

Gopal et al. 2007 – Am J Physiol Gastrointest Liver Physiol
Expression and functional features of NaCT, a sodium-coupled citrate transporter, in human and rat livers and cell lines.

 

Inoue et al. 2002 – Biochem Biophys Res Comm
Human Na+-coupled citrate transporter (NaCT): primary structure, genomic organization, and transport function.

 

Rogina et al. 2000 – Science
Extended Life-Span Conferred by Cotransporter Gene Mutations in Drosophila (discovery of INDY: I am Not Dead Yet).